Aligos Therapeutics Stock Net Asset
| ALGS Stock | USD 22.99 1.64 7.68% |
Aligos Therapeutics fundamentals help investors to digest information that contributes to Aligos Therapeutics' financial success or failures. It also enables traders to predict the movement of Aligos Stock. The fundamental analysis module provides a way to measure Aligos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aligos Therapeutics stock.
Aligos | Net Asset |
Aligos Therapeutics Company Net Asset Analysis
Aligos Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Aligos Therapeutics Net Asset | 151.53 M |
Most of Aligos Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aligos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aligos Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Aligos Therapeutics is extremely important. It helps to project a fair market value of Aligos Stock properly, considering its historical fundamentals such as Net Asset. Since Aligos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aligos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aligos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Aligos Total Assets
Total Assets |
|
Based on the recorded statements, Aligos Therapeutics has a Net Asset of 151.53 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Aligos Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aligos Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aligos Therapeutics could also be used in its relative valuation, which is a method of valuing Aligos Therapeutics by comparing valuation metrics of similar companies.Aligos Therapeutics is currently under evaluation in net asset category among its peers.
Aligos Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aligos Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aligos Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aligos Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aligos Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aligos Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aligos Therapeutics' value.| Shares | Baker Bros Advisors Lp | 2024-09-30 | 83.1 K | Hillhouse Capital Advisors, Ltd. | 2024-09-30 | 76.2 K | Ubs O'connor Llc | 2024-09-30 | 67.1 K | Vanguard Group Inc | 2024-09-30 | 63.8 K | Millennium Management Llc | 2024-06-30 | 29.9 K | Geode Capital Management, Llc | 2024-09-30 | 24.1 K | Cwm, Llc Duplicate | 2024-06-30 | 16.9 K | Jane Street Group Llc | 2024-06-30 | 13.7 K | Renaissance Technologies Corp | 2024-09-30 | 13.4 K | Adage Capital Partners Gp Llc | 2024-06-30 | 5 M | Bank Of America Corp | 2024-06-30 | 816 K |
Aligos Fundamentals
| Return On Equity | -1.47 | ||||
| Return On Asset | -0.67 | ||||
| Operating Margin | (15.86) % | ||||
| Current Valuation | 10.81 M | ||||
| Shares Outstanding | 3.46 M | ||||
| Shares Owned By Insiders | 17.79 % | ||||
| Shares Owned By Institutions | 48.80 % | ||||
| Number Of Shares Shorted | 291.5 K | ||||
| Price To Book | 1.53 X | ||||
| Price To Sales | 13.75 X | ||||
| Revenue | 15.53 M | ||||
| Gross Profit | (71.17 M) | ||||
| EBITDA | (85.06 M) | ||||
| Net Income | (87.68 M) | ||||
| Cash And Equivalents | 159.34 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 11.14 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 5.30 X | ||||
| Book Value Per Share | 15.07 X | ||||
| Cash Flow From Operations | (79 M) | ||||
| Short Ratio | 0.73 X | ||||
| Earnings Per Share | (7.25) X | ||||
| Target Price | 103.33 | ||||
| Number Of Employees | 68 | ||||
| Beta | 2.12 | ||||
| Market Capitalization | 82.49 M | ||||
| Total Asset | 151.53 M | ||||
| Retained Earnings | (486.8 M) | ||||
| Working Capital | 117.18 M | ||||
| Net Asset | 151.53 M |
About Aligos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aligos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aligos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aligos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.